We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Rentokil Initial Plc | RTO | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 8.00 | 2.04% | 399.60 | 16:35:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 393.90 | 392.80 | 401.30 | 399.60 | 391.60 |
| Industry Sector |
|---|
| SUPPORT SERVICES |
| Top Posts |
|---|
Posted at 19/12/2024 18:38 by hedgehog 100 Some great news yesterday from ROC:-18/12/2024 09:26 RNS Regulatory News Rockpool Acquisitions PLC Potential reverse takeover European Lingerie Group LSE:ROC Rockpool Acquisitions Plc "Heads of Agreement signed with European Lingerie Group, AB ("ELG AB" or "the Target") Potential Reverse Takeover and Temporary Suspension of Listing ... The consideration for the Acquisition, if it is concluded, ("the Price") will be settled by the issue of new ordinary shares of Rockpool, valuing each ordinary share at 10p per share (compared with a mid-market price of 2.85p at close on Tuesday 17th December 2024). The Price will be agreed by Rockpool and the sellers in light of the valuation at which the Company's brokers anticipate being able to procure investors to subscribe for new ordinary shares in the Placing as well as the price at which the Target raises funds in the Pre-RTO Fundraising. ..." So a 10p/share RTO valuation for current ROC shares. Compared to a current ROC share price (suspended) of 2.85p, market cap. £362,663 (12,725,003 shares in issue). But an increase 'on paper' of over 4.4 times my 2.25p tip price here ... barely a week ago. |
Posted at 16/12/2024 07:51 by halfpenny SMART INVESTORS ADD £31 MILLION.Get On The Train !! Future just got Brighter as Deals Ahead. |
Posted at 09/12/2024 13:59 by hedgehog 100 09/12/2024 08:00 RNS Regulatory News Aura Renewable Acquisitions PLC Proposed Initial Transaction LSE:ARA Aura Renewable Acquisitions Plc"Proposed Initial Transaction - acquisition of Zero Carbon Technologies Limited Aura Renewable Acquisitions Plc, a UK-based company, whose objective is to invest in the global renewable energy sector supply chain and thereby build shareholder value, is pleased to announce that as of 6 December 2024, it has entered into heads of terms (the "Heads of Terms") with Zero Carbon Technologies Limited ("ZCT"), a UK incorporated company with planned battery recycling operations in Europe, which set out the key terms for ARA to acquire 100% of the issued share capital of ZCT, in consideration for the issue of ordinary shares in ARA to the shareholders of ZCT, subject to due diligence, as well as the negotiation and execution of definitive agreements (the "Proposed Acquisition", to which ARA and ZCT are the "parties"). The Heads of Terms are non-binding except with regard to confidentiality, exclusivity, costs and other customary conditions for a transaction of this nature which are binding. About Zero Carbon Technologies Limited The directors of Zero Carbon Technologies Limited expect that it will be an innovative leader in the battery recycling sector, dedicated to providing sustainable solutions for the recycling of Lead-Acid batteries ("LAB") and Lithium-ion batteries. Leveraging intellectual property licensed from Regenerate Technology Global and Cambridge University, ZCT plans to expand its operations into EV battery recycling. It intends to use advanced recycling technology to recover black mass containing critical materials, including copper, lithium, cobalt, manganese and nickel. ZCT was incorporated in the UK on 26 May 2021, and has a non-binding agreement for a proposed business combination (which it is intended will be completed prior to the Proposed Acquisition) with Clean Tech Lab S.L. ("CTL") (incorporated in Spain). ZCT is in the process of acquiring land, buildings, and equipment with a view to establishing two advanced recycling facilities in La Mancha province, Spain. The board of directors of ZCT considers that the sites will be strategically located for both logistical efficiency and regulatory advantages. ZCT will manage the operations of these planned plants, with the first facility in Puertollano intended to begin commissioning in Q1 2025, followed by a facility in Montalbo anticipated to begin commissioning in Q4 2025. With an estimated potential combined annual processing capacity of 75,000 tonnes of LAB -equivalent to approximately 1.5 million used units - ZCT aims to recover up to 99% of the materials in these batteries, including by enhancing lead oxide, a valuable composite containing recycling minerals. This capability will be driven by proprietary technology, licensed from Regenerate and Cambridge University, which is expected to allow efficient recycling of LAB by the installation and commissioning of the plant within nine months from inception. ... Valuation: ZCT's pre-money valuation is required to be a minimum of £30 Million. The pre-money value of ARA will be calculated as 10% of the pre-money value of the merged group, excluding the proceeds of the proposed Capital Raise and the Target Financing, such that ARA shareholders will hold 10.0% on an undiluted basis of the shares in ARA immediately after completion of the Proposed Acquisition, excluding those issued to investors under the proposed Target Financing and Capital Raise. ..." So a £3M. valuation for current ARA shares, with 10,500,000 shares currently in issue, equates to a valuation of 28.57p per ARA share. Compared to a current ARA share price (suspended) of 4.25p, market cap. £446,250. I.e. an increase 'on paper' of over 6.7 times: over 570%! |
Posted at 25/9/2024 18:56 by davius In London's FTSE 100, Rentokil jumped 4.2% after an activist investor secured a seat on the board.Rentokil appointed Brian Baldwin to its board as a non-executive director with effect from October 1. Baldwin is the head of research of Trian Fund Management LP, an investment management firm, run by Nelson Peltz. Previously, Trian has agitated for change at amongst others, Walt Disney Co, although it was ultimately defeated. "Trian believes Rentokil has significant potential and runway for growth that can be achieved by leveraging its strong brands and market leading positions, particularly in the US. I look forward to working with management and the board to identify options to help drive long-term value that will benefit all stakeholders," Baldwin said in a statement. There has been speculation that Trian will push for the company to take a US listing, where the majority of its business is conducted. Earlier in September, Rentokil warned slower growth in North America and the strong pound will dent full-year profit. It was the latest blow for the firm, which cut guidance in July, and also back in October 2023. |
Posted at 26/7/2024 08:02 by halfpenny Breaking News ...Last month, Trian Fund Management LP, the firm of activist investor Nelson Peltz, became a top 10 shareholder, according to Bloomberg. More news on Takeover expected over the weekend and days to come... Forget the Olympics as RTO is a World Class Winner. Future getting Brighter as Demand Increases. |
Posted at 13/2/2024 08:41 by sunshine today I can understand that, that policy has served me well in the past.That said LOOK how many of the shells ( 40 ) to start, are gone today taking all investors cash with them. 31 dead, and all down bar 3. Good luck. |
Posted at 19/10/2023 20:04 by essentialinvestor Back in the day they offered office services, less specialist.If you read through the FY presentation on the investor relations sight it will answer most of your questions. |
Posted at 23/8/2023 19:58 by hedgehog 100 The shell company ASHI floated at 3p per share in June, market cap. £1.841M., compared to net cash of £717K., including its net IPO proceeds.That didn't look cheap, but to its credit it has suspended (at 2.75p) for a RTO, valued at well over £100M., just two and a half months later:- 06/06/2023 08:01 UK Regulatory (RNS & others) Ashington Innovation PLC Ashington - Admission to trading on the LSE LSE:ASHI Ashington Innovation Plc "Admission to trading on the London Stock Exchange Ashington Innovation plc, a special purpose acquisition company ("SPAC") aiming to benefit from favourable price conditions for companies in the financial services technology (fintech) and deep technology (deep tech) sectors, is pleased to announce that its entire issued ordinary share capital, consisting of 61,397,900 ordinary shares, was admitted to the Standard Listing Segment of the Official List of the Financial Conduct Authority, and to trading on the London Stock Exchange's Main Market for listed securities at 8.00 a.m. today, under the ticker "ASHI". ... About Ashington Innovation plc Ashington Innovation PLC is a special purpose acquisition company (SPAC), formed with the intention of acquiring businesses operating in the technology sector, in particular the financial services technology and deep technology sectors. The Company believes that in the increasingly fast-changing global environment there will be an abundance of opportunities to acquire existing businesses in the technology sector, and in particular businesses that possess and utilise proprietary technologies and own applicable intellectual property. The Company is not limited to any specific geographic region in identifying its target companies. Both Jason Drummond and Jason Smart, directors of the Company, bring a wealth of experience in founding and building successful companies across a diverse range of sectors. www.ashingtoninnovat 17/08/2023 08:10 UK Regulatory (RNS & others) Ashington Innovation PLC Heads of Terms Signed LSE:ASHI Ashington Innovation Plc "Heads of Terms Signed Proposed Reverse Takeover of Cell Therapy Limited Suspension of Listing Conditional Acquisition of Cell Therapy Limited Ashington Innovation (LSE:ASHI), the Special Purpose Acquisition Company (SPAC) established to acquire businesses primarily in the technology sector, is pleased to announce that the Company has entered into a non-binding term sheet (the "Term Sheet") with Cell Therapy Limited ("Cell Therapy") pursuant to which Ashington Innovation will acquire 100% of the total issued equity for GBP135 million in an all share transaction (the "Transaction"). Cell Therapy is a clinical stage biotechnology firm with a portfolio of patented cellular medicines with a lead program that successfully completed an early-stage human clinical trial in heart failure. The Directors of Ashington Innovation consider the Transaction to represent a transformational, value enhancing transaction for shareholders, which is fully aligned with the Company's growth strategy. Cell Therapy's product and patent portfolio provides a platform to develop leading medicines, which have been validated in a human clinical trial and through granted patents in the US, UK, EU and Asia. To fund the Transaction, Ashington Innovation will be seeking to carry out a placing of new ordinary shares to new and existing investors ("Placing") to raise funds of up to GBP3 million to finance the drug development program and working capital. As such, the Transaction is conditional, inter alia, on the completion of due diligence, definitive sale and purchase documentation, obtaining the necessary regulatory approvals from the FCA and the Takeover Panel, a successful Placing, and the passing of necessary resolutions to approve the Transaction by the shareholders of the Company at a duly convened general meeting. Suspension of Listing As the proposed acquisition, if it proceeds, will constitute a Reverse Takeover under the Listing Rules, the Company's ordinary shares shall be suspended pending the publication of a prospectus or an announcement that the proposed Transaction is not proceeding. Any restoration of the listing is subject to the approval of the FCA. At this stage, there can be no guarantee that the proposed Transaction will complete nor as to the final terms of the proposed Transaction. Further announcements and updates will be made in due course. Jason Smart, Founder of Ashington Innovation, commented: "We are delighted to have agreed a heads of terms to acquire Cell Therapy. During the past few months, we have reviewed numerous projects and believe the proposed acquisition meets our stated objective of identifying a potentially extremely valuable entity capable of sustainable development and with significant technological advantages. The directors believe that the regenerative medicine and biotechnology sector presents compelling opportunities to create value for shareholders and the proposed acquisition presents a high-quality target with an experienced and expert leadership. This is a very exciting opportunity to bring a scalable business with a strong track record to the public markets." " Ashington Innovation (ASHI):- |
Posted at 24/6/2023 12:50 by hedgehog 100 One of mii favourite shells at the moment:-Milton Capital (MII) 0.9p Market cap. £0.9M. 04/10/2022 07:10 UK Regulatory (RNS & others) Milton Capital PLC First Day of Dealings LSE:MII Milton Capital Plc "Admission to a Standard Listing and to trading on the Main Market of the London Stock Exchange First day of dealings Admission details Milton Capital plc (LSE: MII) announces that 100,000,000 Ordinary Shares will today be admitted to the Standard Segment of the Official List of the Financial Conduct Authority and to trading on the Main Market for listed securities of the London Stock Exchange. The placing of new ordinary shares has successfully raised a total of GBP950,000, at a placing price of GBP0.01 per share. Highlights: -- One Price for All - All investors have come in at the same IPO price; no Founder Shares or pre-IPO rounds; no warrants; no options. -- No Advisory/Broking Fees - The Company's advisor and broker, Peterhouse Capital, has agreed to waive all advisory fees and commission on all funds raised at the IPO and will receive no annual retainer. -- Capped listing and on-going costs - - The IPO costs, including all accounting, legal, PR and Exchange fees, which amount to GBP55,955, have been capped at GBP50,000 by Peterhouse Capital and as such, post Admission, the Company will have net proceeds of GBP950,000 ; - Total costs for the first full year after listing are also capped at GBP50,000. -- No ongoing director salaries - The Company's directors will receive no salaries or consultancy fees; compensation will only be received by way of a success fee on the completion of an acquisition approved by shareholders. Strategy The Company was formed to undertake one or more acquisitions of a majority interest in a company or business. Any such acquisition undertaken by the Company will be treated as a reverse takeover for the purposes of Chapter 5 of the Listing Rules. The directors intend to search initially for acquisition opportunities in the technology sector. The theme focus for the prospective acquisition is megatrends. This includes sectors such as space, artificial intelligence, machine learning and blockchain technology. Megatrends are powerful, transformative forces that can change the global economy, business and society. They drive innovation and redefine business strategies and have a meaningful impact on how we live, how we spend our money and how we invest. The disrupters in particular have produced dynamic profits for early-stage shareholders. Admission details Prior to Admission, the Company had 5,000,000 Existing Ordinary Shares in issue and conditional on Admission issued 95,000,000 Placing Shares. All Existing Ordinary Shares and Placing Shares were issued at a price of GBP0.01 per share. ..." |
Posted at 10/6/2023 16:20 by hedgehog 100 Hedgehog 100 18 Nov '22 - 18:00 - 1004 of 1012 Edit 0 0 0"Thanks Sweet Karolina. So to summarise:- • 'Pre-existing' main-listed shells that listed by 2.12.21 can still arrange a sub £30M. RTO (minimum only £0.7M.), up until 1.12.23 completed FCA submissions; after that they can still arrange RTOs, but subject to the £30M. minimum. • 'New' main-listed shells can still float with a sub £30M. market cap. (previous minimum only £0.7M.), up until 2.6.23*, if they completed their FCA submission by 2.12.21. - But these shells will be subject to the £30M. RTO minimum. *Presumably actual listing, rather than just another submission." The shell Ashington Innovation (ASHI) floated on the main market 4 days ago, and has a current market cap. at 3.5p of £2.15M.; its final prospectus date was 1st. June, so it could well be that the the 2nd. June deadline relates to the final prospectus date. ASHI's prospectus dated 1st. June 2023:- 06/06/2023 08:01 UK Regulatory (RNS & others) Ashington Innovation PLC Ashington - Admission to trading on the LSE LSE:ASHI Ashington Innovation Plc "Ashington Innovation plc, a special purpose acquisition company ("SPAC") aiming to benefit from favourable price conditions for companies in the financial services technology (fintech) and deep technology (deep tech) sectors, is pleased to announce that its entire issued ordinary share capital, consisting of 61,397,900 ordinary shares, was admitted to the Standard Listing Segment of the Official List of the Financial Conduct Authority, and to trading on the London Stock Exchange's Main Market for listed securities at 8.00 a.m. today, under the ticker "ASHI". ..." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
